Pliva

This article is about the Croatian company. For the river in Bosnia and Herzegovina, see Pliva (river). For the waterfall in Bosnia and Herzegovina, see Pliva Waterfall.
Pliva d.o.o.
Company typeSubsidiary
IndustryPharmaceutical industry
Founded1921; 103 years ago (1921)
HeadquartersZagreb, Croatia
Key people
Mihael Furjan (CEO)
ProductsGeneric drugs
Revenue$1.174 billion (2005)
$0.336 billion (2005)
Number of employees
1,700
ParentTeva Pharmaceuticals
Websitewww.pliva.com
Footnotes / references
[1]
Pliva headquarters in Zagreb
Azithromycin, also known as Sumamed, is one of the world's best-selling antibiotics.

Pliva d.o.o. is a pharmaceutical company based in Zagreb, Croatia that primarily manufactures and sells generic drugs. It is a subsidiary of Teva Pharmaceuticals.

Pliva is one of the world's largest producers of generic Adderall.[citation needed]

History

The company was founded in 1921.[1]

A team of Pliva's researchers, Gabrijela Kobrehel, Gorjana Radobolja-Lazarevski and Zrinka Tamburašev led by Dr. Slobodan Đokić, discovered azithromycin in 1980.[2]

In June 2002, the company acquired Sidmak for $152.9 million.[3]

Also in June 2002, Zeljko Peric, the chief financial officer of the company, resigned.[4]

In May 2004, the company received approval from the Food and Drug Administration to sell trospium chloride.[5]

In June 2005, the company received approval to sell a generic version of erythropoietin in Croatia.[6]

In November 2005, the company received approval from the Food and Drug Administration to sell a generic version of Azithromycin,[7] Citalopram,[8] and Ondansetron.[9]

In October 2006, Barr Pharmaceuticals acquired Pliva.[10]

On December 23, 2008, Barr Pharmaceuticals was acquired by Teva Pharmaceuticals and the company became part of Teva Active Pharmaceutical Ingredients (TAPI).[11]

References

  1. ^ a b "Company Profile". Pliva.
  2. ^ Mutak, Stjepan (2007). "Azalides from Azithromycin to New Azalide Derivatives". The Journal of Antibiotics. 60 (2): 85–122. doi:10.1038/ja.2007.10. ISSN 0021-8820.
  3. ^ "PLIVA announces acquisition of US-based Sidmak" (Press release). Pliva. June 11, 2002.
  4. ^ "PLIVA announces management changes" (Press release). Pliva. June 27, 2002.
  5. ^ "PLIVA Announces FDA Approval of SANCTURA" (Press release). Pliva. May 31, 2004.
  6. ^ "PLIVA Registers generic EPO in Croatia" (Press release). Pliva. June 21, 2005.
  7. ^ "PLIVA Announces Approval for Azithromycin Tablets" (Press release). Pliva. November 15, 2005.
  8. ^ "PLIVA Announces Approval for Citalopram Hydrobromide Tablets" (Press release). Pliva. November 3, 2005.
  9. ^ "PLIVA Announces Approval for Ondansetron Hydrochloride ODT" (Press release). Pliva. November 21, 2005.
  10. ^ "Barr Acquires PLIVA d.d." (Press release). Pliva. October 12, 2006.
  11. ^ "TEVA COMPLETES ACQUISITION OF BARR" (Press release). Pliva. December 23, 2008.